media – Page 373 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

CureVac seeks to accelerate vaccine infringement case against Pfizer and BioNTech

Paul Schloesser Associate Editor CureVac is going on the offensive against Pfizer and BioNTech, saying that it will seek to accelerate its litigation around patents related to the manufacture of the Covid-19 vaccine Comirnaty. The German biotech company announced Friday that the case, which originally launched in the US last summer, has been transferred from the federal district court of Massachusetts to the eastern district court in Virginia as part of an effort to speed up the litigation, potentially allowing for a trial as soon as next year. On top of that transfer going through, CureVac filed a 94-page document Friday, filled with a broader counterclaims that say Pfizer and BioNTech infringed on nine of its US patents — eight of which it claims are owned by CureVac and the ninth by CureVac Manufacturing. These patents range from producing mRNA to vaccine design and manufacturing. CureVac first filed a lawsuit ...
- Source: drugdu
- 118
- May 23, 2023
Cholera outbreak kills 10 in S.Africa

An outbreak of cholera has killed at least 10 people near South Africa’s capital of Pretoria, health authorities said Sunday, urging the public to be “extra vigilant”. The Department of Health in Pretoria’s Gauteng province said 95 people visited a local hospital since Monday showing cholera symptoms, including diarrhea, stomach cramps and nausea. Lab tests on Sunday confirmed at least 19 were cases of cholera, the department said in a statement, adding 37 people were still undergoing treatment. The victims included a three-year-old child and nine adults. Nomantu Nkomo-Ralehoko, the provincial head for health, said additional staff, including medics and nurses, were being mobilized to deal with the outbreak, which was centered in Hammanskraal, an area north of Pretoria. “We would like to reiterate and urge the public to avoid known or suspected contaminated food, water and surfaces and wash hands thoroughly with soap before handling food or after using ...
- Source: drugdu
- 121
- May 23, 2023
NICE recommends Cara’s Kapruvia to treat CKD-associated pruritus

Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) have announced that the US’s National Institute for Health and Care Excellence (NICE) has recommended Kapruvia (difelikefalin) to treat chronic kidney disease (CKD)-associated pruritus. Kapruvia has been recommenced to treat moderate-to-severe CKD-associated pruritus in adult patients who are undergoing haemodialysis. This will allow patients in Northern Ireland, England, and Wales to get access to Kapruvia. The recommendation from NICE follows the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) authorisation of Kapruvia for the same indication in April last year. Cara Therapeutics president and CEO Christopher Posner said: “We are pleased that Kapruvia will be available to CKD patients in England, Wales and Northern Ireland who are undergoing haemodialysis and suffering from moderate-to-severe CKD-associated pruritus. “Together with VFMCRP, we are committed to bringing our first-of-its kind therapy to providers and patients around the world to help change the way pruritus ...
- Source: drugdu
- 216
- May 23, 2023
First diagnostic test for long COVID is available to patients across Australia

The first diagnostic test for long COVID is now available to patients across Australia. The test can help physicians diagnose long COVID by differentiating it from other diseases with similar symptoms, and to design personalized treatment approaches. Persistent COVID, or long COVID, is a multiorgan symptomatic complex with symptoms persisting over time. It affects patients who have suffered from acute COVID-19 infection. It is estimated by the US Centers for Disease Control that about 20% – 30% of patients who have suffered from COVID-19 may develop long COVID. The typical symptoms of long COVID, such as fatigue, brain fog, shortness of breath, insomnia, and a wide range of cardiovascular issues, are certainly not unique to one condition. A diagnostic test to identify patients with long COVID, using objective measures of immune biomarkers, is an essential first step for treatment. The simple blood-based test was developed by diagnostic testing company IGeneX ...
- Source: drugdu
- 115
- May 23, 2023
Study finds significant amount of clotting in the arteries of patients with STEMI and COVID-19

The latest analysis from The North American COVID-19 STEMI (NACMI) was presented today as late-breaking clinical research at the Society for Cardiovascular Angiography & Interventions (SCAI) 2023 Scientific Sessions. The findings show patients with an ST-elevated myocardial infarction, or STEMI, and COVID-19 had a significant amount of clotting in their arteries both before and after intervention. Importantly, clots were seen in multiple arteries in close to 30% of patients, a phenomenon observed in less than 5% of patients with heart attacks who do not have COVID-19. In the United States, someone experiences a heart attack every 40 seconds (CDC). Of these patients, more than 25% will experience a more severe type of heart attack, an ST-elevated myocardial infarction, or STEMI caused by the sudden, total blockage of a coronary artery. Pre-COVID-19 mortality in STEMI patients was below 5% (JACC). Previous NACMI research has shown that mortality jumps to 20% to ...
- Source: drugdu
- 211
- May 22, 2023
Hand-gesture decoding using data from noninvasive brain imaging

Researchers from University of California San Diego have found a way to distinguish among hand gestures that people are making by examining only data from noninvasive brain imaging, without information from the hands themselves. The results are an early step in developing a non-invasive brain-computer interface that may one day allow patients with paralysis, amputated limbs or other physical challenges to use their mind to control a device that assists with everyday tasks. The research, recently published online ahead of print in the journal Cerebral Cortex, represents the best results thus far in distinguishing single-hand gestures using a completely noninvasive technique, in this case, magnetoencephalography (MEG). “Our goal was to bypass invasive components,” said the paper’s senior author Mingxiong Huang, PhD, co-director of the MEG Center at the Qualcomm Institute at UC San Diego. Huang is also affiliated with the Department of Electrical and Computer Engineering at the UC San ...
- Source: drugdu
- 140
- May 22, 2023
Novel gene-editing strategy leverages unusual genetic alteration to block HIV spread in cells

Genetic alterations that give rise to a rare, fatal disorder known as MOGS-CDG paradoxically also protect cells against infection by viruses. Now, scientists at the Lewis Katz School of Medicine at Temple University have harnessed this unusual protective ability in a novel gene-editing strategy aimed at eliminating HIV-1 infection with no adverse effects on cell mortality. The new approach, described online April 28 in the journal Molecular Therapy—Nucleic Acids, is based on a combination of two gene-editing constructs, one that targets HIV-1 DNA and one that targets a gene called MOGS—defects in which cause MOGS-CDG. In cells from persons infected with HIV-1, the Temple researchers show that disrupting the virus’s DNA while also deliberately altering MOGS blocks the production of infectious HIV-1 particles. The discovery opens up new avenues in the development of a cure for HIV/AIDS. Proper MOGS function is essential for glycosylation, a process by which some cellular ...
- Source: drugdu
- 113
- May 22, 2023
Phase I trial demonstrates first pharmacological treatment able to improve cardiac function in stiff-heart syndrome

Transthyretin-related cardiac amyloidosis is a progressive disease characterized by the deposition of amyloid protein fibrils in the heart. Amyloid fibril deposition thickens and stiffens the heart walls, and the disease is also known as stiff-heart syndrome. The accumulation of amyloid fibrils causes heart failure, and patients suffer from fluid retention, fatigue, and arrhythmias. The disease can be caused by genetic mutations or related to aging. Prognosis is poor, and untreated patients survive for an average of just 3 years. Now, the results of a study published in the The New England Journal of Medicine (NEJM) promise to radically alter the prospects of patients with this disease. The study was led by Dr. Pablo Garcia-Pavía, who heads the Inherited Cardiac Diseases Section at Hospital Universitario Puerta de Hierro and is a research scientist at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) and within the Spanish cardiovascular research network (CIBERCV). Coinciding with ...
- Source: drugdu
- 112
- May 22, 2023
Heart attack patients with strong legs have better prognosis, finds research

People with strong legs are less likely to develop heart failure after a heart attack, according to research presented today at Heart Failure 2023, a scientific congress of the European Society of Cardiology (ESC). Myocardial infarction is the most common cause of heart failure, with around 6–9% of heart attack patients going on to develop the condition. Previous research has shown that having strong quadriceps is associated with a lower risk of death in patients with coronary artery disease. This study tested the hypothesis that leg strength is associated with a lower risk of developing heart failure after acute myocardial infarction. The study included 932 patients hospitalized in 2007 to 2020 with acute myocardial infarction who did not have heart failure prior to the admission and did not develop heart failure complications during their hospital stay. The median age was 66 years and 753 participants (81%) were men. Maximal quadriceps ...
- Source: drugdu
- 103
- May 22, 2023
Specially coated titanium reduces risk of clots on prostheses

An international research team led by the German University of Jena has now developed a promising approach to significantly reducing blood clotting on the heart valve material titanium. Around 25,000 artificial heart valves are implanted in Germany per year because the original heart valve is damaged, for example, by an infection. The mechanical heart valves are made of titanium dioxide, among other materials, and last for many years. However, because blood tends to clot on contact with these material surfaces, there is a risk of blood clots forming on the surface of mechanical heart valves. This can become life-threatening if such blood clots break away from the materials. For this reason, most people with mechanical heart valves take medication throughout their lives to reduce blood clotting. An international research team has now developed a promising approach to significantly reducing blood clotting on the heart valve material titanium. The results of ...
- Source: drugdu
- 122
- May 22, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.